Radiologic and Genomic Evolution of Individual Metastases during HER2 Blockade in Colorectal Cancer

Giulia Siravegna, Luca Lazzari, Giovanni Crisafulli, Andrea Sartore-Bianchi, Benedetta Mussolin, Andrea Cassingena, Cosimo Martino, Richard B. Lanman, Rebecca J. Nagy, Stephen Fairclough, Giuseppe Rospo, Giorgio Corti, Alice Bartolini, Pamela Arcella, Monica Montone, Francesca Lodi, Annalisa Lorenzato, Alice Vanzati, Emanuele Valtorta, Giovanni CappelloAndrea Bertotti, Sara Lonardi, Vittorina Zagonel, Francesco Leone, Mariangela Russo, Antonella Balsamo, Mauro Truini, Federica Di Nicolantonio, Alessio Amatu, Erica Bonazzina, Silvia Ghezzi, Daniele Regge, Angelo Vanzulli, Livio Trusolino, Salvatore Siena, Silvia Marsoni, Alberto Bardelli

Research output: Contribution to journalArticlepeer-review

Abstract

Siravegna et al. identify genetic events associated with ERBB2 amplified metastatic colorectal cancers resistant to trastuzumab plus lapatinib treatment and reveal lesion-private evolutionary patterns. Analyses of metastases from a patient unveil metastasis-specific evolution and pharmacologic vulnerabilities.

Original languageEnglish
Pages (from-to)148-162.e7
JournalCancer Cell
Volume34
Issue number1
DOIs
Publication statusPublished - Jul 9 2018

Keywords

  • clonal evolution
  • colorectal cancer
  • ctDNA
  • HER2 amplification
  • lapatinib
  • liquid biopsy
  • rapid autopsy
  • resistance
  • targeted therapy
  • trastuzumab

ASJC Scopus subject areas

  • Oncology
  • Cell Biology
  • Cancer Research

Fingerprint Dive into the research topics of 'Radiologic and Genomic Evolution of Individual Metastases during HER2 Blockade in Colorectal Cancer'. Together they form a unique fingerprint.

Cite this